Dexcom launches over-the-counter continuous glucose sensors in the US
Adds pricing details in paragraphs 3, background throughout
Aug 26 (Reuters) - Dexcom DXCM.O said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99.
Stelo wascleared by the U.S. health regulator in March for use by adults aged 18 and older who do not use insulin, making it the the first continuous glucose monitor available for over-the-counter sales.
Patients could buy a pack of two sensors at a one-time price of $99 or opt for a subscription to get a monthly delivery for $89, Dexcom said.
In June, rival Abbott LaboratoriesABT.N received the regulator's clearance for two similar devices,Libre Rio and Lingo, for adults with and without diabetes, respectively.
Abbott had said it plans to launch Lingo in the U.S. this summer.
Lingo has been available in Britain since January for 120-150 pounds ($152-$190) per month.
Dexcom's Stelo uses a wearable sensor, paired with an application on the user's smartphone or other smart device to continuously measure blood glucose levels.
The device is not for individuals with problematic hypoglycemia or low blood sugar as it is not designed to alert the user about this potentially dangerous condition.
Reporting by Mariam Sunny in Bengaluru; Editing by Mrigank Dhaniwala and Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
